GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (NAS:SESN) » Definitions » WACC %

Sesen Bio (Sesen Bio) WACC % :10.5% (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sesen Bio WACC %?

As of today (2024-05-11), Sesen Bio's weighted average cost of capital is 10.5%%. Sesen Bio's ROIC % is 0.00% (calculated using TTM income statement data). Sesen Bio earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


Sesen Bio WACC % Historical Data

The historical data trend for Sesen Bio's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sesen Bio WACC % Chart

Sesen Bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.33 -6.48 3.87 2.96 13.42

Sesen Bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.96 6.52 11.92 13.13 13.42

Competitive Comparison of Sesen Bio's WACC %

For the Biotechnology subindustry, Sesen Bio's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sesen Bio's WACC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sesen Bio's WACC % distribution charts can be found below:

* The bar in red indicates where Sesen Bio's WACC % falls into.



Sesen Bio WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Sesen Bio's market capitalization (E) is $127.953 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2022, Sesen Bio's latest one-year quarterly average Book Value of Debt (D) is $0 Mil.
a) weight of equity = E / (E + D) = 127.953 / (127.953 + 0) = 1
b) weight of debt = D / (E + D) = 0 / (127.953 + 0) = 0

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.5%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Sesen Bio's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.5% + 1 * 6% = 10.5%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Dec. 2022, Sesen Bio's interest expense (positive number) was $-0 Mil. Its total Book Value of Debt (D) is $0 Mil.
Cost of Debt = -0 / 0 = %.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -3.875 / -23.759 = 16.31%.

Sesen Bio's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=1*10.5%+0*%*(1 - 16.31%)
=10.5%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sesen Bio  (NAS:SESN) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sesen Bio's weighted average cost of capital is 10.5%%. Sesen Bio's ROIC % is 0.00% (calculated using TTM income statement data). Sesen Bio earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.


Related Terms

Sesen Bio (Sesen Bio) Business Description

Traded in Other Exchanges
N/A
Address
245 First Street, Suite 1800, Cambridge, MA, USA, 02142
Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.
Executives
Modernatx, Inc. 10 percent owner 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly director, officer: President and CEO C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris officer: Chief Financial Officer 397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba director 158 FILMORE STREET, DENVER CO 80206
Bjorn Odlander director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Michael Klichinsky officer: Chief Scientific Officer C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok director C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits director C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Elly Ryu officer: Principal Accounting Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Glen C Macdonald officer: Chief Technology Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Monica Forbes officer: Chief Financial Officer 3344 NORTH TORREY PINES CT., SUITE 200, SAN DIEGO CA 92037
Thomas R Cannell director, officer: President and CEO C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Mark Sullivan officer: General Counsel & Secretary 1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054

Sesen Bio (Sesen Bio) Headlines

From GuruFocus

Sesen Bio Provides Strategic Update

By Business Wire Business Wire 05-03-2022

Sesen Bio Announces Productive CMC Type A Meeting with the FDA

By Business Wire Business Wire 11-01-2021